Combined Fluoxetine and Metformin Treatment Potentiates Antidepressant Efficacy Increasing IGF2 Expression in the Dorsal Hippocampus

Silvia Poggini, Maria Teresa Golia, Silvia Alboni, Giampaolo Milior, Livio Pepè Sciarria, Aurelia Viglione, Gloria Matte Bon, Nicoletta Brunello, Stefano Puglisi-Allegra, Cristina Limatola, Laura Maggi, Igor Branchi

Research output: Contribution to journalArticle

Abstract

An increasing number of studies show that selective serotonin reuptake inhibitors (SSRIs) exert their therapeutic action, at least in part, by amplifying the influence of the living environment on mood. As a consequence, when administered in a favorable environment, SSRIs lead to a reduction of symptoms, but in stressful conditions, they show limited efficacy. Therefore, novel therapeutic approaches able to neutralize the influence of the stressful environment on treatment are needed. The aim of our study was to test whether, in a mouse model of depression, the combined administration of SSRI fluoxetine and metformin, a drug able to improve the metabolic profile, counteracts the limited efficacy of fluoxetine alone when administered in stressful conditions. Indeed, metabolic alterations are associated to both the onset of major depression and the antidepressant efficacy. To this goal, adult C57BL/6 male mice were exposed to stress for 6 weeks; the first two weeks was aimed at generating a mouse model of depression. During the remaining 4 weeks, mice received one of the following treatments: vehicle, fluoxetine, metformin, or a combination of fluoxetine and metformin. We measured liking- and wanting-type anhedonia as behavioral phenotypes of depression and assessed the expression levels of selected genes involved in major depressive disorder and antidepressant response in the dorsal and ventral hippocampus, which are differently involved in the depressive symptomatology. The combined treatment was more effective than fluoxetine alone in ameliorating the depressive phenotype after one week of treatment. This was associated to an increase in IGF2 mRNA expression and enhanced long-term potentiation, specifically in the dorsal hippocampus, at the end of treatment. Overall, the present results show that, when administered in stressful conditions, the combined fluoxetine and metformin treatment may represent a more effective approach than fluoxetine alone in a short term. Finally, our findings highlight the relevance of polypharmacological strategy as effective interventions to increase the efficacy of the antidepressant drugs currently available.

Original languageEnglish
Number of pages1
JournalNeural Plasticity
Volume2019
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Fluoxetine
Metformin
Antidepressive Agents
Hippocampus
Serotonin Uptake Inhibitors
Depression
Anhedonia
Phenotype
Metabolome
Long-Term Potentiation
Major Depressive Disorder
Messenger RNA
Therapeutics
Pharmaceutical Preparations
Genes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Combined Fluoxetine and Metformin Treatment Potentiates Antidepressant Efficacy Increasing IGF2 Expression in the Dorsal Hippocampus. / Poggini, Silvia; Golia, Maria Teresa; Alboni, Silvia; Milior, Giampaolo; Sciarria, Livio Pepè; Viglione, Aurelia; Matte Bon, Gloria; Brunello, Nicoletta; Puglisi-Allegra, Stefano; Limatola, Cristina; Maggi, Laura; Branchi, Igor.

In: Neural Plasticity, Vol. 2019, 01.01.2019.

Research output: Contribution to journalArticle

Poggini, Silvia ; Golia, Maria Teresa ; Alboni, Silvia ; Milior, Giampaolo ; Sciarria, Livio Pepè ; Viglione, Aurelia ; Matte Bon, Gloria ; Brunello, Nicoletta ; Puglisi-Allegra, Stefano ; Limatola, Cristina ; Maggi, Laura ; Branchi, Igor. / Combined Fluoxetine and Metformin Treatment Potentiates Antidepressant Efficacy Increasing IGF2 Expression in the Dorsal Hippocampus. In: Neural Plasticity. 2019 ; Vol. 2019.
@article{f12550fcff1f4802a1f350c9f272bcff,
title = "Combined Fluoxetine and Metformin Treatment Potentiates Antidepressant Efficacy Increasing IGF2 Expression in the Dorsal Hippocampus",
abstract = "An increasing number of studies show that selective serotonin reuptake inhibitors (SSRIs) exert their therapeutic action, at least in part, by amplifying the influence of the living environment on mood. As a consequence, when administered in a favorable environment, SSRIs lead to a reduction of symptoms, but in stressful conditions, they show limited efficacy. Therefore, novel therapeutic approaches able to neutralize the influence of the stressful environment on treatment are needed. The aim of our study was to test whether, in a mouse model of depression, the combined administration of SSRI fluoxetine and metformin, a drug able to improve the metabolic profile, counteracts the limited efficacy of fluoxetine alone when administered in stressful conditions. Indeed, metabolic alterations are associated to both the onset of major depression and the antidepressant efficacy. To this goal, adult C57BL/6 male mice were exposed to stress for 6 weeks; the first two weeks was aimed at generating a mouse model of depression. During the remaining 4 weeks, mice received one of the following treatments: vehicle, fluoxetine, metformin, or a combination of fluoxetine and metformin. We measured liking- and wanting-type anhedonia as behavioral phenotypes of depression and assessed the expression levels of selected genes involved in major depressive disorder and antidepressant response in the dorsal and ventral hippocampus, which are differently involved in the depressive symptomatology. The combined treatment was more effective than fluoxetine alone in ameliorating the depressive phenotype after one week of treatment. This was associated to an increase in IGF2 mRNA expression and enhanced long-term potentiation, specifically in the dorsal hippocampus, at the end of treatment. Overall, the present results show that, when administered in stressful conditions, the combined fluoxetine and metformin treatment may represent a more effective approach than fluoxetine alone in a short term. Finally, our findings highlight the relevance of polypharmacological strategy as effective interventions to increase the efficacy of the antidepressant drugs currently available.",
author = "Silvia Poggini and Golia, {Maria Teresa} and Silvia Alboni and Giampaolo Milior and Sciarria, {Livio Pep{\`e}} and Aurelia Viglione and {Matte Bon}, Gloria and Nicoletta Brunello and Stefano Puglisi-Allegra and Cristina Limatola and Laura Maggi and Igor Branchi",
year = "2019",
month = "1",
day = "1",
doi = "10.1155/2019/4651031",
language = "English",
volume = "2019",
journal = "Neural Plasticity",
issn = "2090-5904",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Combined Fluoxetine and Metformin Treatment Potentiates Antidepressant Efficacy Increasing IGF2 Expression in the Dorsal Hippocampus

AU - Poggini, Silvia

AU - Golia, Maria Teresa

AU - Alboni, Silvia

AU - Milior, Giampaolo

AU - Sciarria, Livio Pepè

AU - Viglione, Aurelia

AU - Matte Bon, Gloria

AU - Brunello, Nicoletta

AU - Puglisi-Allegra, Stefano

AU - Limatola, Cristina

AU - Maggi, Laura

AU - Branchi, Igor

PY - 2019/1/1

Y1 - 2019/1/1

N2 - An increasing number of studies show that selective serotonin reuptake inhibitors (SSRIs) exert their therapeutic action, at least in part, by amplifying the influence of the living environment on mood. As a consequence, when administered in a favorable environment, SSRIs lead to a reduction of symptoms, but in stressful conditions, they show limited efficacy. Therefore, novel therapeutic approaches able to neutralize the influence of the stressful environment on treatment are needed. The aim of our study was to test whether, in a mouse model of depression, the combined administration of SSRI fluoxetine and metformin, a drug able to improve the metabolic profile, counteracts the limited efficacy of fluoxetine alone when administered in stressful conditions. Indeed, metabolic alterations are associated to both the onset of major depression and the antidepressant efficacy. To this goal, adult C57BL/6 male mice were exposed to stress for 6 weeks; the first two weeks was aimed at generating a mouse model of depression. During the remaining 4 weeks, mice received one of the following treatments: vehicle, fluoxetine, metformin, or a combination of fluoxetine and metformin. We measured liking- and wanting-type anhedonia as behavioral phenotypes of depression and assessed the expression levels of selected genes involved in major depressive disorder and antidepressant response in the dorsal and ventral hippocampus, which are differently involved in the depressive symptomatology. The combined treatment was more effective than fluoxetine alone in ameliorating the depressive phenotype after one week of treatment. This was associated to an increase in IGF2 mRNA expression and enhanced long-term potentiation, specifically in the dorsal hippocampus, at the end of treatment. Overall, the present results show that, when administered in stressful conditions, the combined fluoxetine and metformin treatment may represent a more effective approach than fluoxetine alone in a short term. Finally, our findings highlight the relevance of polypharmacological strategy as effective interventions to increase the efficacy of the antidepressant drugs currently available.

AB - An increasing number of studies show that selective serotonin reuptake inhibitors (SSRIs) exert their therapeutic action, at least in part, by amplifying the influence of the living environment on mood. As a consequence, when administered in a favorable environment, SSRIs lead to a reduction of symptoms, but in stressful conditions, they show limited efficacy. Therefore, novel therapeutic approaches able to neutralize the influence of the stressful environment on treatment are needed. The aim of our study was to test whether, in a mouse model of depression, the combined administration of SSRI fluoxetine and metformin, a drug able to improve the metabolic profile, counteracts the limited efficacy of fluoxetine alone when administered in stressful conditions. Indeed, metabolic alterations are associated to both the onset of major depression and the antidepressant efficacy. To this goal, adult C57BL/6 male mice were exposed to stress for 6 weeks; the first two weeks was aimed at generating a mouse model of depression. During the remaining 4 weeks, mice received one of the following treatments: vehicle, fluoxetine, metformin, or a combination of fluoxetine and metformin. We measured liking- and wanting-type anhedonia as behavioral phenotypes of depression and assessed the expression levels of selected genes involved in major depressive disorder and antidepressant response in the dorsal and ventral hippocampus, which are differently involved in the depressive symptomatology. The combined treatment was more effective than fluoxetine alone in ameliorating the depressive phenotype after one week of treatment. This was associated to an increase in IGF2 mRNA expression and enhanced long-term potentiation, specifically in the dorsal hippocampus, at the end of treatment. Overall, the present results show that, when administered in stressful conditions, the combined fluoxetine and metformin treatment may represent a more effective approach than fluoxetine alone in a short term. Finally, our findings highlight the relevance of polypharmacological strategy as effective interventions to increase the efficacy of the antidepressant drugs currently available.

UR - http://www.scopus.com/inward/record.url?scp=85062167019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062167019&partnerID=8YFLogxK

U2 - 10.1155/2019/4651031

DO - 10.1155/2019/4651031

M3 - Article

C2 - 30804991

AN - SCOPUS:85062167019

VL - 2019

JO - Neural Plasticity

JF - Neural Plasticity

SN - 2090-5904

ER -